We used this data to control for prostate cancer screening tendencies since countries with a higher GDP are more prone to PCa screening.
However, recent improvements in treatment (e.g., three-dimensional conformal radiotherapy, intensity-modulated radiotherapy [ 34]) and symptom control for prostate cancer may have contributed to the low symptom frequency in the items assessed in the BS and TS domains.
Recent data show that FTY720 (Fingolimod), an agonist of S1PRs 1, 3, 4, and 5, which is clinically used as a functional S1PR antagonist in treatment of multiple sclerosis is the first clinically applicable SphK1 inhibitor and has a radiosensitising potential providing improved local control for prostate tumours (Pchejetski et al, 2010a).
However, the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial, 53 which was designed to control for prostate cancer screening, observed an inverse association between cruciferous vegetable intake and risk of extraprostatic prostate cancer (RR = 0.60; 95% CI = 0.36 0.98, 1.1 serving vs 0.1 serving/day).
Overall, the collaborative analysis included data on rs4430796 for 19,640 cancer cases and 21,929 controls; for prostate cancer there were 11,145 cases and 9,650 controls, while for all other cancers there were 8,495 cases and 12,279 controls.
The collected data on rs7501939 included 26,923 cases and 49,085 controls; for prostate cancer there were 12,898 cases and 40,371 controls, while for the other cancers there were 14,025 cases and 43,893 controls.
Expression levels of circulating miRNAs have shown some potential at distinguishing cancer patients and healthy controls for prostate [ 9], ovarian [ 10], lung [ 11, 12], and breast cancers [ 13].
Specimens of nodular hyperplasia (N=30) were used as a control for nonmalignant prostate.
Because nodular hyperplasia of the prostate gland (NHPG) is a common histopathological finding in males of this age group and hyperplastic changes were also detected in perimalignant benign areas of carcinoma specimens, tissue specimens affected by NHPG were used as a control for the prostate gland not affected by the malignant disease.
A.E., B.M., J.M., and M.W.D. reviewed, annotated and performed data entry, editing, and data quality control for all prostate cancer references, G.Z., X.W., H.L. implemented the Genome Browser with the assistance of W.J., V.R., and S.T. and formatted and uploaded the ChromSorter PC.gff files.
A new method is presented for synthesizing dose-response data for biochemical control of prostate cancer according to study design (randomized vs. nonrandomized) and risk group (low vs. intermediate-high).
